Carregant...
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
There is no standard therapy for refractory acute myeloid leukemia (AML), but several salvage therapies are available (National Comprehensive Cancer Network [NCCN], 2018). Recently, there have been major developments in the treatment of AML focusing on the development of targeted and novel therapies...
Guardat en:
| Publicat a: | J Adv Pract Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Harborside Press LLC
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7779565/ https://ncbi.nlm.nih.gov/pubmed/33457062 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.5.7 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|